175 related articles for article (PubMed ID: 10690534)
21. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
22. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking.
Suzuki H; Takahashi T; Kuroishi T; Suyama M; Ariyoshi Y; Takahashi T; Ueda R
Cancer Res; 1992 Feb; 52(3):734-6. PubMed ID: 1310070
[TBL] [Abstract][Full Text] [Related]
23. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
Curigliano G; Ferretti G; Mandalà M; De Pas T; Calabrò MG; Solli P; Noberasc C; de Braud F
Anticancer Res; 2001; 21(5):3461-9. PubMed ID: 11848510
[TBL] [Abstract][Full Text] [Related]
24. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
25. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
[TBL] [Abstract][Full Text] [Related]
28. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
29. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
30. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
31. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
32. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract][Full Text] [Related]
33. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
[TBL] [Abstract][Full Text] [Related]
34. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
35. p53AIP1 expression can be a prognostic marker in non-small cell lung cancer.
Yamashita SI; Masuda Y; Yoshida N; Matsuzaki H; Kurizaki T; Haga Y; Ikei S; Miyawaki M; Kawano Y; Chujyo M; Kawahara K
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):148-51. PubMed ID: 17851056
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
[TBL] [Abstract][Full Text] [Related]
37. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.
Horio Y; Takahashi T; Kuroishi T; Hibi K; Suyama M; Niimi T; Shimokata K; Yamakawa K; Nakamura Y; Ueda R
Cancer Res; 1993 Jan; 53(1):1-4. PubMed ID: 8380124
[TBL] [Abstract][Full Text] [Related]
40. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
Mitsudomi T; Steinberg SM; Oie HK; Mulshine JL; Phelps R; Viallet J; Pass H; Minna JD; Gazdar AF
Cancer Res; 1991 Sep; 51(18):4999-5002. PubMed ID: 1654209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]